Chen Xue, Gao Feng, Zhang Jie
Department of Gastroenterology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Scand J Gastroenterol. 2022 Oct;57(10):1195-1201. doi: 10.1080/00365521.2022.2073184. Epub 2022 May 9.
Aspirin can reduce cardiovascular disease risk; however, it can increase the risk of gastrointestinal injury. have some protective effects; however, there are few studies on their effects on humans. This study investigates the effects of complex capsule treatment on the aspirin-related small intestinal mucosal injury.
This single-center, prospective, randomized controlled clinical trial included 69 patients using enteric-coated aspirin for >1 month between May and December 2019. After baseline magnetically controlled capsule endoscopy (MCCE), patients with aspirin-related small intestinal mucosal injury were randomly assigned (1:1) to receive enteric-coated aspirin complex capsules containing a combination of , , and (probiotics group) or enteric-coated aspirin only (control group) for 2 months. After treatment, the patient underwent MCCE again. The primary outcome was the change in small intestinal mucosal injury scores from baseline to post-intervention.
Twenty-five patients in the probiotics group and 28 in the control group completed the trial. The decrease in small intestinal mucosal injury scores from baseline to post-intervention was significantly greater in the probiotics group than that in the control group ( < .001). The improvement rates of red spots and erosions in the probiotics group were higher compared with the control group ( = .027 and .022, respectively), and the improvement rate of small intestinal ulcers in the probiotics group was 75.0%; however, there was no improvement in the control group.
complex capsules can ameliorate aspirin-related small intestinal mucosal injury.
阿司匹林可降低心血管疾病风险；然而，它会增加胃肠道损伤的风险。[某些物质]具有一定的保护作用；然而，关于它们对人类影响的研究较少。本研究调查了[某种]复合胶囊治疗对阿司匹林相关小肠黏膜损伤的影响。
这项单中心、前瞻性、随机对照临床试验纳入了2019年5月至12月期间使用肠溶阿司匹林超过1个月的69例患者。在进行基线磁控胶囊内镜检查（MCCE）后，将患有阿司匹林相关小肠黏膜损伤的患者随机分配（1:1）接受含有[具体成分1]、[具体成分2]和[具体成分3]（益生菌组）的肠溶阿司匹林复合胶囊或仅接受肠溶阿司匹林（对照组）治疗2个月。治疗后，患者再次接受MCCE。主要结局是从基线到干预后小肠黏膜损伤评分的变化。
益生菌组25例患者和对照组28例患者完成了试验。从基线到干预后，益生菌组小肠黏膜损伤评分的下降幅度显著大于对照组（P<0.001）。与对照组相比，益生菌组红斑和糜烂的改善率更高（分别为P=0.027和0.022），益生菌组小肠溃疡的改善率为75.0%；然而，对照组没有改善。
[某种]复合胶囊可改善阿司匹林相关小肠黏膜损伤。
